Acyclic And Contains At Least One Carbon Atom Between The Phosphorus Atoms Patents (Class 514/108)
-
Patent number: 7871992Abstract: The present invention describes organophosphorus compounds of general formula (I) their preparation and their uses in the activation of gamma/delta T-cells, in the screening of GcpE and LytB enzyme inhibitors and in the prophylaxis and treatment of diseases in humans and animals.Type: GrantFiled: June 11, 2008Date of Patent: January 18, 2011Assignee: Bioagency AGInventors: Hassan Jomaa, Oliver Wolf, Boran Altincicek, Mathias Eberl, Martin Hintz, Ann-Kristin Kollas, Armin Reichenberg, Jochen Wiesner
-
Publication number: 20110008461Abstract: A PEPCK inhibitor can include identifying a molecule that has a size capable of fitting into and interacting with the PEPCK binding site and at least one of the following: (a) a first terminal substituent having co-planar atoms acting as metal ligands to the active site metal ion PEPCK; (b) at least one of an atom or substituent at positions 2 or 3 from the first terminal substituent includes a neutral carbon center or include an oxygen, sulfur, selenium, or other atom with similar physiochemical properties; (c) at least one of an atom or substituent at positions 2 or 3 from the first terminal substituent is devoid of an electropositive atom or substituents; or (d) a second terminal substituent opposite of the first terminal substituent, said second terminal substituent having an atom that is a hydrogen boding acceptor and/or is negatively charged.Type: ApplicationFiled: July 12, 2010Publication date: January 13, 2011Inventors: Gerald Carlson, Todd Holyoak, Sarah Sullivan, Rose Mary Stiffin
-
Publication number: 20110002879Abstract: The invention provides a combination comprising a cytotoxic compound, a signalling inhibitor, an ancillary agent, or two or more further anti-cancer agents, and a compound having the formula (Ib): or salts or tautomers or N-oxides or solvates thereof; wherein X is a group R1-A-NR4—; A is a bond, C?O, NRg(C?O) or O(C?O) wherein Rg is hydrogen or C1-4 hydrocarbyl optionally substituted by hydroxy or C1-4 alkoxy; Y is a bond or an alkylene chain of 1, 2 or 3 carbon atoms in length; R1 is a carbocyclic or heterocyclic group having from 3 to 12 ring members; or a C1-8 hydrocarbyl group optionally substituted by one or more substituents selected from fluorine, hydroxy, C1-4 hydrocarbyloxy, amino, mono- or di-C1-4 hydrocarbylamino, and carbocyclic or heterocyclic groups having from 3 to 12 ring members, and wherein 1 or 2 of the carbon atoms of the hydrocarbyl group may optionally be replaced by an atom or group selected from O, S, NH, SO, SO2; R2 is hydrogen; halogen; C1-4 alkoxy (e.g.Type: ApplicationFiled: April 1, 2010Publication date: January 6, 2011Applicant: ASTEX THERAPEUTICS LIMITEDInventors: Jayne Elizabeth CURRY, John Francis LYONS, Matthew Simon SQUIRES, Neil Thomas THOMPSON, Kyla Merriom THOMPSON, Paul Graham WYATT, Neil James GALLAGHER
-
Publication number: 20110003010Abstract: Phosphoric esters comprise A) one or more structural units derived from substances of component a), the substances of component a) being selected from orthophosphoric acid and one or more of its derivatives, B) one or more structural units derived from substances of component b), the substances of component b) being selected from one or more compounds of formula (I) R2—O—(CH2CH2O)u(C3H6O)v(DO)w—H??(I) and C) one or more structural units derived from substances of component c), the substances of component c) being selected from one or more diols of formula (II) HO—(CH2CH2O)a(C3H6O)b(DO)c—H??(II) where the sum total a+b+c is ?1 and the phosphoric ester contains 2 or more phosphorus atoms per molecule which are bridged via a structural unit derived from the compounds of formula (II). The phosphoric esters of the invention are very useful in the manufacture of cosmetic, pharmaceutical and dermatological compositions.Type: ApplicationFiled: July 29, 2008Publication date: January 6, 2011Applicant: CLARIANT FINANCE (BVI) LIMITEDInventors: Peter Klug, Franz-Xaver Scherl, Waltraud Simsch, Adelgunde Oberhauser
-
Publication number: 20100317622Abstract: The present invention provides a method of efficiently and stably producing LCPUFA-PL. Specifically, the invention provides a method for producing phospholipids that contain LCPUFA as a constituent (LCPUFA-PL), wherein lipid producing cells producing lipids that contain long-chain polyunsaturated fatty acids (LCPUFA) are used as a starting material, the method including a PL extracting step of extracting phospholipids (PL) from defatted cells obtained by extracting triglyceride (TG)-containing oil or fat from the lipid producing cells.Type: ApplicationFiled: August 4, 2010Publication date: December 16, 2010Applicant: Suntory Holdings LimitedInventors: Hiroshi Kawashima, Motoo Sumida, Akiko Shiraishi
-
Patent number: 7846474Abstract: This procedure consists in the first stage, of the administration of enough quantity of bisphosphonate preparation during the necessary period of time to acquire a degree of volumetric mineral density of the cortical tissue of application, within the normal range (average.+?.1 DS). Then the administration of the bisphosphonate preparation is interrupted in order to enable the development of the sectional momentum of inertia. The length of the second stage can be determined by means of a tomography. That is to say, that the periods of administration or non-administration of the mineralizing agent are defined or controlled by precise osteologic variables and therefore are not fixed. If during the second stage the cortical mineral density drops by 6-10% of the maximum value previously obtained, administration of bisphosphonate preparation should be resumed until the corresponding maximum adjusted value is reached again.Type: GrantFiled: January 18, 2008Date of Patent: December 7, 2010Assignee: Gador S.A.Inventors: Emilio J.A. Roldan, Anibal Perez-Lloret
-
Publication number: 20100305056Abstract: Several parasites responsible for mammalian diseases are dependent on cysteine protease for various life-cycle functions. Inhibition or decreasing function of these proteases can be useful in the treatment and/or prevention of these parasitic diseases including; toxoplasmosis, malaria, African trypanosomiasis, Chagas disease, leishmaniasis, schistosomiasis, amebiasis, giardiasis, clonorchiasis, opisthorchiasis, paragonimiasis, fasciolopsiasis, lymphatic filariasis, onchocerciasis, dracunculiasis, ascariasis, trichuriasis, strongyloidiasis, trichostrongyliasis, trichomoniasis or cestodiasis.Type: ApplicationFiled: November 26, 2008Publication date: December 2, 2010Applicant: Merck Frosst Canada Ltd.Inventors: Elise Isabel, Christophe Mellon, Christian Beaulieu
-
Patent number: 7820197Abstract: A bisphosphonic acid derivative-containing percutaneous preparation of an excellent percutaneous permeability, comprising a bisphosphonic acid derivative such as incadronic acid, minodronic acid, etc., or pharmaceutically acceptable salts thereof, a solubilizing agent for the derivative or pharmaceutically acceptable salts thereof, and an amphiphilic solubilizing auxiliary agent, which may optionally contain a suspension-type base such as a polyvalent alcohol, a higher fatty acid ester, a liquid hydrocarbon or a vegetable oil, etc. This preparation has an excellent percutaneous permeability, reduces burdens on the patient, does not deteriorate the patient's compliance even in the administration over a prolonged period of time and can achieve the therapeutic effects in a short period of time.Type: GrantFiled: February 13, 2003Date of Patent: October 26, 2010Assignee: Astellas Pharma Inc.Inventors: Yasuhiro Tsuji, Kei Tamura, Yuuhiro Yamazaki, Yoshihiro Sawai
-
Publication number: 20100266670Abstract: This invention is to provide a transdermal administration type pharmaceutical preparation which has better transdermal absorptivity, safety and practical application for treatment of bone calcium metabolic diseases, such as high calcium in blood which resulted from osteoporosis, osteitis deformans and malignant tumors.Type: ApplicationFiled: December 9, 2008Publication date: October 21, 2010Inventors: Akira Yamamoto, Toshiyasu Sakane, Hidemasa Katsumi, Fumio Kamiyama, Ying-shu Quan
-
Publication number: 20100267633Abstract: The invention relates to substituted N-(4-oxo-3,4-dihydroquinazolin-2-yl)butanamid derivatives which modulate androgen receptors to treat conditions such as: osteoporosis, peridontal disease, bone fracture, frailty, and sarcopenia.Type: ApplicationFiled: September 22, 2006Publication date: October 21, 2010Inventors: Barbara Hanney, Yuntae Kim, Helen J. Mitchell, Jeffrey D. Musselman, James J. Perkins
-
Publication number: 20100247607Abstract: The invention relates to devices, methods and formulation for subcutaneous administration of a bisphosphonate. In such a device, a drug core, comprising a bisphosphonate, is disposed in a tube. The devices may be administered to a patient in need of subcutaneously wherein the release of the bisphosphonate is desired to provide sustained release of a therapeutically effective dose of the bisphosphonate.Type: ApplicationFiled: March 26, 2010Publication date: September 30, 2010Applicant: pSivida US, Inc.Inventor: Paul Ashton
-
Publication number: 20100247640Abstract: The invention relates to a pharmaceutical composition and oral dosage forms comprising a bisphosphonate in combination with an enhancer to enhance intestinal delivery of the bisphosphonate to the underlying circulation. Preferably, the enhancer is a medium chain fatty acid or a medium chain fatty acid derivative having a carbon chain length of from 6 to 20 carbon atoms, and the solid oral dosage form is a controlled release dosage form such as a delayed release dosage form.Type: ApplicationFiled: April 26, 2010Publication date: September 30, 2010Inventor: Thomas W. Leonard
-
Publication number: 20100233304Abstract: Compositions comprising one or more unsaturated fatty acids and one or more nitric oxide releasing compounds, and methods for using such compositions for enhancing cognitive function, reducing or preventing a decline of social interaction, reducing or preventing age-related behavioral changes, increasing trainability, maintaining optimal brain function, facilitating learning and memory, reducing memory loss, retarding brain aging, preventing or treating strokes, and preventing or treating dementia in an animal. Preferably, the compositions are food compositions useful for enhancing cognitive function in humans and companion animals.Type: ApplicationFiled: December 19, 2008Publication date: September 16, 2010Inventor: Yuanlong Pan
-
Publication number: 20100222875Abstract: Methods for forming porous stent coatings are disclosed.Type: ApplicationFiled: August 8, 2007Publication date: September 2, 2010Applicant: Abbott Cardiovascular Systems Inc.Inventor: Stephen Dirk Pacetti
-
Publication number: 20100216747Abstract: An object of the present invention is to provide a preventive drug and a therapeutic drug for diseases caused by abnormal bone metabolism, especially osteoporosis, which is more effective than conventional drugs. Combined use of N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}-benzamidine, or a salt thereof; and at least one compound selected from the group consisting of etidronic acid, clodronic acid, pamidronic acid, tiludronic acid, risedronic acid, minodronic acid, ibandronic acid, zoledronic acid, and salts thereof can exert higher bone resorption inhibitory effect and provide a preventive effect and a therapeutic effect for diseases caused by abnormal bone metabolism, especially osteoporosis as compared with administration of the respective agents respectively.Type: ApplicationFiled: August 1, 2008Publication date: August 26, 2010Applicant: TEIJIN PHARMA LIMITEDInventors: Eiji Ochiai, Miyuki Nishiga, Kenichiro Takagi, Yoshiaki Azuma
-
Patent number: 7781420Abstract: The invention describes the use of clodronic acid, its addition salts or esters as active ingredient for the preparation of a pharmaceutical for treating podotrochlosis with associated osteoporosis in horses.Type: GrantFiled: November 9, 2006Date of Patent: August 24, 2010Assignee: Omnimedic GbRInventor: Michael Frevel
-
Publication number: 20100209499Abstract: The invention relates to a solid oral dosage form comprising a pharmaceutically active ingredient in combination with an enhancer which enhances the bioavailability and/or the absorption of the active ingredient. Accordingly, a solid oral dosage form comprises a drug and an enhancer wherein the enhancer is a medium chain fatty acid ester, ether or salt or a derivative of a medium chain fatty acid, which is, preferably, solid at room temperature and which has a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is controlled release dosage form such as a delayed release dosage form.Type: ApplicationFiled: April 27, 2010Publication date: August 19, 2010Inventors: Kenneth I. Cumming, Zebunnissa Ramtoola
-
Publication number: 20100197637Abstract: The present invention refers to a pharmaceutical composition of a bisphosphonic acid or salt thereof, and an excipient thereof, and a method of treating disorder characterized by pathologically increased bone resorption comprising orally administering at least 150% of the expected efficious daily dose of a bisphosphonic acid or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients thereof and administering the dose at a period of one two or three consecutive days per month.Type: ApplicationFiled: April 8, 2010Publication date: August 5, 2010Inventors: Frieder Bauss, Bernhard Pichler, Stephen Turley
-
Publication number: 20100197636Abstract: The present invention relates to a macroporous, resorbable and injectable apatitic calcium-phosphate cement with a high compressive strength useful as bone cement and releasing a bone resorption inhibitor, preparation method and uses thereof.Type: ApplicationFiled: February 13, 2008Publication date: August 5, 2010Inventors: Jean-Michel Bouler, Bruno Bujoli, Pascal Janvier, Ibrahim Khairoun, Jean-Noël Argenson
-
Publication number: 20100179110Abstract: The present invention relates to pharmaceutical compositions containing a bisphosphonic acid in combination with a non-activated metabolite of vitamin D for oral administration. The compositions of the invention either do not contain or contain only low concentrations of a glidant. Also provided are methods for preparing such compositions and methods of use thereof, for preventing or treating abnormal bone resorption in mammals.Type: ApplicationFiled: December 19, 2007Publication date: July 15, 2010Inventors: Mostafa Akbarieh, Fazal M. Mohideen, Shetal Shah
-
Patent number: 7749543Abstract: The invention relates to a combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor, said preparation being adapted for (a) the administration of parathyroid hormone during a period of approximately 6 to 24 months; (b) after the administration of parathyroid hormone has been terminated, the administration of a bone resorption inhibitor during a period of approximately 12 to 36 months.Type: GrantFiled: January 9, 2009Date of Patent: July 6, 2010Assignee: NPS Pharmaceuticals, Inc.Inventors: John Dietrich, Sverker Ljunghall, Sven Sjogren
-
Publication number: 20100168067Abstract: This invention relates to the finding that the presence of polymorphisms in and around the farnesyl diphosphate synthase (FDPS) gene is predictive of the densitometric response of patients with bone disorders, such as osteoporosis, subsequent to commencing treatment with amino-bisphosphonates. Methods relating to the identification of individuals having bone disorders which are responsive to bisphosphonates and predicting the responsiveness of individuals with bone disorders to treatment with a bisphosphonate are provided.Type: ApplicationFiled: March 19, 2007Publication date: July 1, 2010Applicant: UCL BUSINESS PLCInventors: John Chamberlain, Halina Fitz-Clarence, Mark Thomas
-
Publication number: 20100158981Abstract: Disclosed herein are implantable medical devices comprising controlled release biodegradable block copolymers or coated with controlled release block copolymers and at least one drug releasable from the block copolymer. The controlled release block copolymers comprise least two blocks selected from the group consisting of polyesters, polyethers, and polyurethanes.Type: ApplicationFiled: February 19, 2010Publication date: June 24, 2010Applicant: Medtronic Vascular, Inc.Inventors: Ya Guo, Peiwen Cheng
-
Publication number: 20100158998Abstract: The present invention provides stable formulations of vitamin D or a derivative thereof, preferably cholecalciferol.Type: ApplicationFiled: December 23, 2009Publication date: June 24, 2010Inventors: Michael Fox, Leon Shakib
-
Publication number: 20100150861Abstract: The present invention relates to the use of pharmaceutically acceptable zinc salts, preferably water soluble zinc salts alone or optionally, in combination with one or more of a protein pump inhibitor (PPI), H2 blocker, anti-H. pylori antibiotic/antimicrobial, cytoprotective agent or a combination agent as otherwise described herein for providing fast action with optional long duration effect in reducing gastric acid secretion, raising the pH of the stomach during resting phase as well as decreasing the duration of stomach acid release during a secretagogue phase and for treating conditions including gastroesophageal reflux disease (GERD), non-erosive reflux disease (NERD), Zollinger-Ellison syndrome (ZE disease), ulcer disease, and gastric cancer, as well as preventing or reducing the likelihood of ulcer disease.Type: ApplicationFiled: July 22, 2008Publication date: June 17, 2010Applicant: YALE UNIVERSITYInventors: John P. Geibel, Philipp Kirchhoff
-
Patent number: 7718634Abstract: The present invention refers to a pharmaceutical composition of a bisphosphonic acid or salt thereof, and an excipient thereof, and a method of treating disorder characterized by pathologically increased bone resorption comprising orally administering at least 150% of the expected efficious daily dose of a bisphosphonic acid or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients thereof and administering the dose at a period of one two or three consecutive days per month.Type: GrantFiled: June 16, 2008Date of Patent: May 18, 2010Assignee: Hoffman-La Roche Inc.Inventors: Frieder Bauss, Bernhard Pichler, Stephen Turley
-
Publication number: 20100120723Abstract: The present invention relates to a lubricant granulate prepared using a hot melt granulation process, or thermal-heat process. The lubricant granulate is useful in facilitating the use of higher concentrations of lubricant than typically possible in pharmaceutical compositions. Also provided are pharmaceutical compositions comprising the lubricant granulate. Such pharmaceutical compositions can contain bisphosphonic acid as the active ingredient and can be suitable for oral administration. The present invention also provides a hot melt process for preparing the lubricant granulate for subsequent use in pharmaceutical compositions.Type: ApplicationFiled: December 19, 2007Publication date: May 13, 2010Inventors: Mostafa Akbarieh, Thinesh Sivarajah, Shetal Shah
-
Publication number: 20100120720Abstract: The invention relates to the use of a hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor and of a farnesyl-pyrophosphate synthase inhibitor, or of one of their associated physiologically acceptable salts, in the preparation of a composition, particularly a pharmaceutical composition, for use in the treatment of human or animal, pathological or nonpathological situations related to the accumulation and/or the persistence of prenylated proteins in cells, such as during progeria (Hutchinson-Gilford syndrome), restrictive dermopathy or physiological aging.Type: ApplicationFiled: July 5, 2007Publication date: May 13, 2010Applicant: UNIVERSITE DE LA MEDITERRANEE AIX-MAR SEILLE IIInventors: Nicolas Levy, Pierre Cau, Carlos Lopez-Otin
-
Publication number: 20100104506Abstract: Nanoparticle-coated medical devices, nanoparticle-containing formulations and methods of using for treating a vascular disease are disclosed. The medical device includes a coating that comprises a plurality of nanoparticles, wherein the nanoparticles comprise one or more bioactive agents encapsulated within, adhered to a surface of or integrated into the structure of the nanoparticles and further comprise one or more contrast enhancing agents encapsulated within, adhered to a surface of or integrated into the structure of the nanoparticles.Type: ApplicationFiled: January 5, 2010Publication date: April 29, 2010Applicant: Abbott Cardiovascular Systems Inc.Inventors: Florian Niklas Ludwig, Syed Faiyaz Ahmed Hossainy, Katsuyuki Murase, Li Zhao, Irina Astafieva
-
Publication number: 20100098632Abstract: This document provides methods and materials related to hydroxyapatite particles. For example, hydroxyapatite particles, methods for making hydroxyapatite particles, and methods for using hydroxyapatite particles are provided herein.Type: ApplicationFiled: July 12, 2007Publication date: April 22, 2010Inventors: Stephen J. Russell, Kah-Whye Peng, Hooi Tin Ong
-
Publication number: 20100075926Abstract: The invention provides methods and compounds for the treatment of neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS (Amyotrophic Lateral Sclerosis), traumatic brain injury, ischemic brain injury or a stroke. In one aspect the compounds are HDAC1 activators. Exemplary HDAC1 activators include metal chelators, iron chelators, deferoxamin, flavonoids, compounds comprising a catechol moity, ginkgetin K, Chembridge 5104434, sciadopilysin, tetrahydrogamboic acid, TAM-11, LY 235959, CGS 19755, SK&F 97541, etidronic acid, levonordefrin, methyldopa, ampicillin trihydrate, D-aspartic acid, gamma-D-glutamylaminomethylsulfonic acid, phenazopyridine to hydrochloride, oxalamine citrate salt, podophyllotoxin, SK&F 97541, (+-)-4-amino-3-(5-chloro-2-thienyl)-butanoic acid, (RS)-(tetrazol-5-yl) glycine, R(+)-SKF-81297, gambogic acid, and derivatives thereof.Type: ApplicationFiled: July 23, 2009Publication date: March 25, 2010Inventors: Li-Huei Tsai, Stephen J. Haggarty, Dohoon Kim
-
Publication number: 20100068211Abstract: A method of preventing or treating ionizing radiation-associated loss of bone mass, bone density or bone strength in a subject is provided, comprising administering to the subject an amount of an antiresorptive or osteoclast inhibiting compound sufficient to prevent or mitigate loss of bone mass, density or strength. A method of preventing or treating radiation-associated increase in the number or activity of osteoclasts in a subject is also provided, comprising administering to the subject an amount of an antiresorptive compound sufficient to reduce osteoclast numbers or reduce osteoclast activity and prevent resulting loss of bone mass, density or strength.Type: ApplicationFiled: February 9, 2009Publication date: March 18, 2010Inventors: Ted A. Bateman, Jeffrey S. Willey
-
Publication number: 20100062037Abstract: Subcutaneous implants obtained by extrusion containing an active ingredient dispersed in a PLGA matrix obtained by grinding an extruded product consisting of a blend of: at least two PLGA having different lactic acid/glycolic acid molar ratios and different weight average molecular weights, or a PLGA and PLA having different weight average molecular weight.Type: ApplicationFiled: August 1, 2007Publication date: March 11, 2010Inventors: Patrice Mauriac, Pierre Marion
-
Publication number: 20100056483Abstract: Disclosed herein are methods and compositions for the treatment and prevention of bone loss. The methods comprise providing a therapeutically effective amount of at least one chelating agent to a subject. The methods further comprise providing a therapeutically effective amount of estrogen or at least one estrogen analogue to a subject. Compositions disclosed herein for the treatment and prevention of bone loss comprise a chelator and estrogen or at least one estrogen analogue. The compositions further comprise at least one of a bisphosphonate, a selective estrogen receptor modulator, or a hormone.Type: ApplicationFiled: April 24, 2009Publication date: March 4, 2010Applicant: OHIO UNIVERSITYInventors: Yang V. Li, Caleb O. Molokwu
-
Publication number: 20100055159Abstract: A bisphosphonic acid derivative-containing percutaneous preparation of an excellent percutaneous permeability, comprising a bisphosphonic acid derivative such as incadronic acid, minodronic acid, etc., or pharmaceutically acceptable salts thereof, a solubilizing agent for the derivative or pharmaceutically acceptable salts thereof, and an amphiphilic solubilizing auxiliary agent, which may optionally contain a suspension-type base such as a polyvalent alcohol, a higher fatty acid ester, a liquid hydrocarbon or a vegetable oil, etc. This preparation has an excellent percutaneous permeability, reduces burdens on the patient, does not deteriorate the patient's compliance even in the administration over a prolonged period of time and can achieve the therapeutic effects in a short period of time.Type: ApplicationFiled: November 4, 2009Publication date: March 4, 2010Inventors: Yasuhiro TSUJI, Kei Tamura, Yuuhiro Yamazaki, Yoshihiro Sawai
-
Publication number: 20100048511Abstract: Provided is a solid dispersion comprising vitamin D or a derivative thereof and a cyclodextrin; a complex formulation for the prevention or treatment of osteophorosis, which includes the solid dispersion and a bisphosphonate; and a method for preparing said complex formulation. The complex formulation can maintain a constant therapeutic level of vitamin D or a derivative thereof through its improved drug stability, while enhancing the patient compliance by minimizing inconvenience and adverse effects when administered to patients.Type: ApplicationFiled: November 6, 2007Publication date: February 25, 2010Applicant: HANMI PHARM CO., LTD.Inventors: Jong Soo Woo, Hong Gi Yi, Ju Nam Jin
-
Publication number: 20100047306Abstract: The present invention relates to depot formulations comprising a poorly water soluble salt of a bisphosphonate forming together with one or more biocompatible polymers. The depot formulation may be in the form of microparticles or implants. The depot formulations are useful for the treatment and prevention of proliferative diseases including cancer.Type: ApplicationFiled: October 3, 2007Publication date: February 25, 2010Applicant: NOVARTIS AGInventors: Rolf Loeffler, Holger Petersen, Juergen Sigg, Gesine Winzenburg
-
Publication number: 20100029596Abstract: The present invention provides a method of treating or preventing osteoporosis comprising administering to a patient in need thereof an effective amount of pharmaceutical composition comprising benzamidine derivative or its salt, and bisphosphonate for the purpose of using simultaneously, separately, or sequentially as active ingredients. As a prophylactic or therapeutic composition for osteoporosis, the combination treatment of the benzamidine derivative and the bisphosphonate compound exhibits excellent inhibitory effect on osteoclast differentiation than the total effect of each individual treatment, thereby being used for the prevention or treatment of osteoporosis.Type: ApplicationFiled: July 31, 2009Publication date: February 4, 2010Applicant: Dong Wha Pharm, Co. Ltd.Inventors: Jei Man RYU, Jin Soo Lee, Yun-Ha Hwang, Young G. Jin, Ki Y. Kim
-
Publication number: 20100029567Abstract: Compounds, methods, uses, compositions, kits and packages for the treatment of imbalance between bone resorption and bone formation, based on uses of 4-phenyl-2 propionamidotetralin (4-P-PDOT) and analogs, derivatives, prodrugs, precursors thereof, and salts thereof, are described.Type: ApplicationFiled: February 15, 2008Publication date: February 4, 2010Applicant: CHU SAINTE-JUSTINEInventors: Alain Moreau, Genevieve Mailhot
-
Publication number: 20100029595Abstract: The present invention relates to a pharmaceutical composition for preventing and treating osteoporosis, comprising N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}benzamidine, 4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}benzamidine, or salts thereof, and alendronic acid or a salt thereof. As a prophylactic or therapeutic composition for osteoporosis, the combination treatment of N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}benzamidine, 4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}-benzamidine, or salts thereof and alendronic acid or a salt thereof exhibits excellent inhibitory effect on osteoclast differentiation, as compared to each individual treatment, thereby being useful for the prevention or treatment of osteoporosis.Type: ApplicationFiled: July 31, 2009Publication date: February 4, 2010Applicant: Dong Wha Pharm. Co., Ltd.Inventors: Jei Man RYU, Jin Soo LEE, Jae Hoon PARK, Yun-Ha HWANG, Duk Kyun CHUNG
-
Publication number: 20100021416Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with otic structure modulating compositions administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and compositions onto or via perfusion into the targeted auris structure(s).Type: ApplicationFiled: July 20, 2009Publication date: January 28, 2010Applicants: OTONOMY, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Jay LICHTER, Benedikt VOLLRATH, Sergio G. DURON, Carl LEBEL, Fabrice PIU, Qiang YE, Luis A. DELLAMARY, Andrew M. TRAMMEL, Michael Christopher SCAIFE, Jeffrey P. HARRIS
-
Publication number: 20100022481Abstract: Drug carriers, methods of synthesizing, and methods of use thereof are provided.Type: ApplicationFiled: August 11, 2009Publication date: January 28, 2010Inventors: Dong Wang, Christopher Hein, Xin-Ming Liu
-
Publication number: 20100015203Abstract: The present invention provides a non-clottable matrix on a solid support comprising immobilized and crosslinked fibrinogen. The matrix may further comprise, in and/or on the matrix, one or several biologically active compound(s) and/or pharmacological substance(s). The matrix may be composed of one or several fibrinogen layer(s). The solid support according to the present invention may be selected from the group consisting of orthopaedic devices, implants, stitches, stents, pins, screws, plates, and sutures.Type: ApplicationFiled: February 26, 2008Publication date: January 21, 2010Applicant: ADDBIO ABInventors: Pentti Tengvall, Ella Cathrine Vikinge
-
Publication number: 20090317460Abstract: A solid dosage form comprises coated particles of bisphosphonate or a pharmaceutically acceptable analogue or derivative thereof.Type: ApplicationFiled: August 24, 2007Publication date: December 24, 2009Applicant: Arrow International LimitedInventors: Peter Persicaner, Craig Judy
-
Publication number: 20090318386Abstract: The invention relates to novel active compound combinations of certain cyclic ketoenols and certain active compounds that together have unexpectedly good insecticidal and acaricidal properties.Type: ApplicationFiled: August 27, 2009Publication date: December 24, 2009Inventors: Reiner Fischer, Christoph Erdelen, Thomas Bretschneider
-
Publication number: 20090312289Abstract: The present invention relates to a new crystalline polymorph of 3-(N-methyl-N-pentyl)amino-1-hydroxypropane-1,1-diphosphonic acid monosodium salt monohydrate (Ibandronate) with the following formulaType: ApplicationFiled: July 17, 2009Publication date: December 17, 2009Inventors: Uwe Eiermann, Bernd Junghans, Bernhard Knipp, Tim Settelkau
-
Publication number: 20090297576Abstract: Described herein are methods and medical devices used to deliver bioactive agents locally to patients in need of treatment and/or prevention of cardiovascular conditions Local delivery of protease-activated receptor 1 (PAR-1) antagonists are described herein from implantable medical devices including, but not limited to, stents.Type: ApplicationFiled: June 2, 2008Publication date: December 3, 2009Applicant: MEDTRONIC VASCULAR, INC.Inventors: Ayala Hezi-Yamit, Jennifer Wong
-
Publication number: 20090281064Abstract: The present invention provides novel solid pharmaceutical dosage forms for oral administration comprising a bisphosphonate, or a pharmaceutically acceptable salt thereof, which bisphosphonate is present in an amount not therapeutically effective when the bisphosphonate is orally administered alone, and a modified amino acid carrier, or a pharmaceutically acceptable salt thereof, which modified amino acid carrier is present in an amount effective to facilitate absorption of the bisphosphonate in the gastrointestinal tract such that the bisphosphonate is therapeutically effective. The ratio of bisphosphonate to modified amino acid carrier is from about 1:30 to about 1:1, respectively. These novel solid pharmaceutical dosage forms are useful in the treatment or control of bone diseases and particular disorders in calcium metabolism, including, for example, osteoporosis, hypercalcaemia of cancer, and the treatment of metastatic bone pain.Type: ApplicationFiled: July 16, 2009Publication date: November 12, 2009Applicant: Emisphere Technologies, Inc.Inventors: Hashim Ahmed, Lewis Bender, Martin Howard Infeld, Shingai Majuru, Wantanee Phuapradit, Navnit Hargovindas Shah, Zhongshui Yu
-
Patent number: 7612052Abstract: The invention relates to a combination which comprises (a) a bisphosphonate, a platinum compound or a vasculostatic compound and (b) an epothilone derivative of formula I wherein A represents O or NRN, wherein RN is hydrogen or lower alkyl, R is hydrogen or lower alkyl, and Z is O or a bond, in which the active ingredients (a) and (b) are present in each case in free form or in the form of a pharmaceutically acceptable salt and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the delay of progression or treatment of a proliferative disease, especially a solid tumor disease; a pharmaceutical composition, a commercial package or product comprising such a combination; the use of such a combination for the preparation of a medicament for the delay of progression or treatment of a proliferative disease and to a method of treatment of a warm-blooded animal.Type: GrantFiled: January 24, 2008Date of Patent: November 3, 2009Assignee: Novartis AGInventors: John David Rothermel, Markus Wartmann, Jeanette Marjorie Wood
-
Publication number: 20090253657Abstract: The invention describes the use of clodronic acid, its addition salts or esters as active ingredient for the preparation of a pharmaceutical for treating podotrochlosis with associated osteoporosis in horses.Type: ApplicationFiled: November 9, 2006Publication date: October 8, 2009Applicant: OMNIMEDIC GBRInventor: Michael Frevel